Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PD-1 inhibitor plus platinum and fluorouracil
10 evidence topics · 7 sources
FDA-approved first-line indication: pembrolizumab with platinum and fluorouracil
KEYNOTE-048 regimen: pembrolizumab with platinum and fluorouracil
KEYNOTE-048 efficacy of pembrolizumab with platinum and fluorouracil at the interim analysis: overall population
| Endpoint | Pembrolizumab with platinum and FU | Cetuximab with platinum and FU |
|---|---|---|
| Participants | “n=281” | “n=278” |
| Median OS, months (95% CI) | “13.0 (10.9, 14.7)” | “10.7 (9.3, 11.7)” |
| OS hazard ratio (95% CI) | “0.77 (0.63, 0.93)” | Reference |
| Median PFS, months (95% CI) | “4.9 (4.7, 6.0)” | “5.1 (4.9, 6.0)” |
| PFS hazard ratio (95% CI) | “0.92 (0.77, 1.10)” | Reference |
| ORR (95% CI) | “36% (30.0, 41.5)” | “36% (30.7, 42.3)” |
| Median duration of response, months (range) | “6.7 (1.6+, 30.4+)” | “4.3 (1.2+, 27.9+)” |
KEYNOTE-048 pembrolizumab with platinum and fluorouracil: final analysis by CPS subgroup
KEYNOTE-048 primary publication: pembrolizumab with chemotherapy overall survival
“Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“235 (85%) of 276 in the pembrolizumab with chemotherapy group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 four-year follow-up: pembrolizumab with chemotherapy
“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 five-year follow-up: pembrolizumab with chemotherapy
“Pembrolizumab-chemotherapy prolonged median OS in the PD-L1 CPS ≥ 20 (HR, 0.63; 95 % CI, 0.47-0.84), CPS ≥ 1 (HR, 0.65; 95 % CI, 0.53-0.79), and total (HR, 0.72; 95 % CI, 0.60-0.86) populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These 5-year follow-up results support the use of pembrolizumab and pembrolizumab-chemotherapy as first-line standards of care for R/M HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab with chemotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1
“For pembrolizumab-chemotherapy versus cetuximab-chemotherapy, the median overall survival was 11.3 versus 10.7 months in the PD-L1 CPS < 1 subgroup (HR, 1.21 [95% CI, 0.76 to 1.94]) and 12.7 versus 9.9 months in the CPS 1-19 subgroup (HR, 0.71 [95% CI, 0.54 to 0.94]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the PD-L1 CPS 1-19 subgroup, the ORR was 29.3% (n = 34; 95% CI, 21.2 to 38.5) for pembrolizumab-chemotherapy versus 33.6% (n = 42; 95% CI, 25.4 to 42.6) for cetuximab-chemotherapy (Table 2 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote